What's in Proton Collaborative Group's pipeline?

Proton Collaborative Group has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Proton Collaborative Group's portfolio?

Top competitors by shared drug class: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/proton-collaborative-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Proton Collaborative Group — Portfolio Competitive Intelligence Brief

Proton Collaborative Group pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Androgen Suppression Therapy	Androgen Suppression Therapy	phase 3	Androgen deprivation therapy (ADT)	Androgen receptor pathway / testosterone / DHT	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Proton Collaborative Group:

Cite this brief

Drug Landscape (2026). Proton Collaborative Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/proton-collaborative-group. Accessed 2026-05-14.